Clinical Trials Directory

Trials / Completed

CompletedNCT00191022

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
185 (planned)
Sponsor
Eli Lilly and Company · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

Conditions

Interventions

TypeNameDescription
DRUGLY686017
DRUGparoxetine
DRUGplacebo

Timeline

Start date
2004-12-01
Completion
2007-01-01
First posted
2005-09-19
Last updated
2007-02-13

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00191022. Inclusion in this directory is not an endorsement.

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder (NCT00191022) · Clinical Trials Directory